Market

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Read More

Related Posts

Oil heads for first monthly drop since November as economic uncertainty weighs

Oil heads for first monthly drop since November as econ...

SS&C Technologies director Michael Zamkow sells $2.03 million in stock

SS&C Technologies director Michael Zamkow sells $2.03 m...

Factbox-Key economic targets expected to be approved by China's parliament

Factbox-Key economic targets expected to be approved by...

‘She’s not working outside the home’: My mother, 63, inherited $100,000. Is she too old to invest in the stock market?

‘She’s not working outside the home’: My mother, 63, in...

South Korea's pension fund logs record 15% investment return in 2024

South Korea's pension fund logs record 15% investment r...

Dell sees its backlog swell as big AI deals come through

Dell sees its backlog swell as big AI deals come through